Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
1456143
Reference Type
Journal Article
Title
Butanol Fraction Containing Berberine or Related Compound From Nexrutine (R) Inhibits NF kappa B Signaling and Induces Apoptosis in Prostate Cancer Cells
Author(s)
Muralimanoharan, SriB; Kunnumakkara, AB; Shylesh, B; Kulkarni, KH; Haiyan, Xu; Ming, Hu; Aggarwal, BB; Rita, G; Kumar, AP
Year
2009
Is Peer Reviewed?
1
Journal
Prostate
ISSN:
0270-4137
EISSN:
1097-0045
Volume
69
Issue
5
Page Numbers
494-504
Language
English
PMID
19107816
DOI
10.1002/pros.20899
Web of Science Id
WOS:000264695600005
Abstract
BACKGROUND:
Epidemiological and laboratory studies support the hypothesis that several plant components influence prostate carcinogenesis and holds promise for disease prevention. Previously we reported that Nexrutine (bark extract from Phellodendron amurense) inhibits proliferation of prostate cancer cells and prostate tumor development in the transgenic adenocarcinoma of mouse prostate (TRAMP) model through modulation of Akt signaling pathway. In the present investigation we conducted studies to further define the mechanism of action of Nexrutine and to identify the active component associated with its biological activity.
METHODS:
Androgen-responsive, androgen-independent human prostate cancer cell lines and tissues from TRAMP mice fed Nexrutine(R) were used in these studies. Activity guided fractionation identified butanol fraction recapitulating the activities of Nexrutine assessed by proliferation assays, apoptotic assays (DAPI and TUNEL staining), transient transfections, gel shift assays and Western blotting. In addition ultra-performance liquid chromatography (UPLC) of butanol fraction was used to identify active component of Nexrutine.
RESULTS:
Butanol fraction recapitulated the activities of Nexrutine in (i) inhibiting proliferation; (ii) inducing apoptosis; and (iii) modulating transcriptional activity of NFkappaB in prostate cancer cells. Our data also indicates that both Nexrutine and butanol fraction modulates NFkappaB transcriptional activity by inhibiting IkappaBalpha phosphorylation. Expression of p65 and phosphorylated IkappaBalpha are high in tumors from TRAMP mice. In contrast dietary administration of Nexrutine reduced expression of p65 and phosphorylated IkappaBalpha in prostate from TRAMP mice. In addition using UPLC, we have identified berberine or closely related compound in the butanol fraction.
CONCLUSION:
The results suggest that berberine or closely related component of butanol fraction may be responsible for the observed biological activities and induce apoptosis in prostate cancer cells by targeting critical cell survival signaling pathways both in vitro and in vivo.
Keywords
nexrutine; apoptosis; fractionation
Tags
IRIS
•
n-Butanol
Database searches
WOS
Source – January 2013 (private)
WOS - 1/2013
Merged reference set - 1/2013
Excluded (not pertinent)
Use in sample prep or assay
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity